Boehringer Ingelheim Announces 2017 Equine Research Recipients

The Advancement in Equine Research Award gives $45,000 for infectious disease research.
Author:
Publish date:

Boehringer Ingelheim (BI) has selected three research proposals to fund as part of its 2017 Advancement in Equine Research Award program. Since 2011 BI has given more than $470,000 to advancing the knowledge of equine infectious disease.

“For the past six years, BI has supported equine research into identifying new disease treatment and prevention methods,” says Dr. Steve Grubbs, DVM, PhD, DACVIM, BI equine technical manager. “Through this program we are committed to helping advance the understanding, diagnosis, and prevention of infectious equine diseases.”

BI congratulates the 2017 Equine Research Award recipients for the following projects:

Nicola Pusterla, DVM, PhD, DACVIM, and Sharon Spier, DVM, PhD, DACVIM, University of California, Davis, School of Veterinary Medicine 

“Investigation of the role of non-steroidal anti-inflammatory and anti-histaminic drugs on the humoral response to a commercial Corynebacterium pseudotuberculosis vaccine given to naïve healthy horses.”

Nicola Pusterla, DVM, PhD, DACVIM, University of California, Davis, School of Veterinary Medicine

“Investigation of the Florida sublineage clade affiliation of equine influenza virus strains using novel multiplex real-time quantitative PCR in nasal secretions submitted to a diagnostic laboratory (2012-2017).”

Rebecca P. Wilkes, DVM, PhD, University of Georgia, Tifton, GA

“Targeted next-generation sequencing panel for detection of equine pathogens.”

Each researcher will receive a grant of $15,000 in support of their study proposal. An independent panel of equine practitioners, university professors, and veterinary medical researchers selected the recipients from numerous proposals. The awards were announced at the recent American Association of Equine Practitioners Annual Convention in San Antonio, Texas.

Applications for the 2018 Equine Research Award will be open next spring. Veterinarians, diagnosticians and public and private researchers in the United States, Canada and Mexico are eligible to submit proposals. For more information visit www.healthyhorses.com.

About the Equine Research Review Board

The Equine Research Review Board, an independent group of equine veterinarians and researchers, selects the Advancement in Equine Research Awards annually. Board members for the 2017 award selection process include:

• Tom Divers, DVM, DACVIM, DACVECC, Cornell University, Ithaca, NY

• Rob Franklin, DVM, DACVIM, FullBucket Veterinary Strength Supplements, Dennis, TX

• Debra Sellon, DVM, PhD, DACVIM, Washington State University, Pullman, WA

• Nathan Slovis, DVM, DACVIM, CHT, Haygard Equine Medical Institute, Lexington, KY

• Julie Wilson, DVM, DACVIM, Turner Wilson Equine Consulting, Stillwater, MN

About Boehringer Ingelheim Animal Health

As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.

Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com